Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of Oral MKC-1 Administered Twice Daily for 14 Consecutive Days Every 3 Weeks in Combination With Pemetrexed

NCT00408226 is registered in ClinicalTrials.gov with CASI pharmaceuticals, Inc. as lead sponsor.

NCT NCT00408226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00408226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of Oral MKC-1 Administered Twice Daily for 14 Consecutive Days Every 3 Weeks in Combination With Pemetrexed
Lead sponsor
CASI pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
October 31, 2006
Completion date
January 31, 2012
Enrollment
27 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, non-small cell lung cancer